Clinical Trials Logo

Strokes Thrombotic clinical trials

View clinical trials related to Strokes Thrombotic.

Filter by:

NCT ID: NCT06275139 Recruiting - Coronary Disease Clinical Trials

Integrated Assessment of Cervicocerebral Vessels to Improve the Brain Injury for CAGB Patients (IACV Study)

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to establish a prospective study to focus on the high-risk stroke population who require coronary artery bypass graft surgery. It will divide the eligible patients into 1:1 group by simple randomization method. The control group adopt the traditional diagnosis and treatment mode, and only head CT plain scan and carotid artery ultrasound shall be performed. If necessary, relevant disciplines would be consulted but no integrated assessment of cervicocerebral vessels be arranged. The final treatment plan would be decided by the surgeon alone. The experimental group adopt the multidisciplinary collaboration and integrated evaluation mode. In addition to routine diagnosis and treatment as above-mentioned, integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment. Based on the above results, surgical plans will be formulated jointly by multiple disciplines including neurologists, vascular surgeons, ICU physicians and cardiac surgeons. Researchers will compare the two groups to investigate whether integrated assessment of cervicocerebral vessels can reduce the incidence of brain injury compared with conventional diagnosis and treatment mode.

NCT ID: NCT06156059 Not yet recruiting - Septic Shock Clinical Trials

Oral Bedtime Melatonin in Critically Ill Patients

Mel-ICU
Start date: February 1, 2025
Phase: Phase 4
Study type: Interventional

Oxidative stress is one of the main mechanisms causing harm in severe infection with septic shock, ischemia-reperfusion injury in resuscitated cardiac arrest and ischemic and hemorrhagic stroke. Melatonin is a potent scavenger of the mediators of oxidative stress, oxygen and nitrogen-reactive species, which directly injure cell structures like walls and DNA and thus cause organ dysfunction. In a previous study we have observed that high-dose oral bedtime melatonin (OBM) is associated with improved organ function in severe Covid-19 patients

NCT ID: NCT05857046 Recruiting - Clinical trials for Stroke, Acute Ischemic

Cerebroprotective Effect of Melatonin in Stroke

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

Stroke is a leading cause of mortality and disability in Mexico and worldwide. Although current treatment strategies focus on removing oclussion, they do not interrupt the signaling cascade of neuronal damage. Thus, the search for a cerebroprotective agent that can protect the entire brain. Melatonin has been proposed as a potential cerebroprotective agent due to its antioxidant, anti-inflammatory, antiapoptotic, and immunomodulatory effects, which oppose the pathophysiological mechanisms of cerebrovascular disease. Melatonin has the potential to improve stroke outcomes and reduce the risk of disability and mortality, making it a promising therapeutic option for stroke patients. To assess the efficacy of melatonin in patients with acute ischemic CVD, improve clinical outcome, and infarct volume.

NCT ID: NCT05325606 Recruiting - Stroke Clinical Trials

Registry-based Stroke in Tunisia

RAV-TUN
Start date: June 1, 2020
Phase:
Study type: Observational [Patient Registry]

Study the prevalence of strokes in the emergency department (ED) and their possible eligibility for thrombolysis.

NCT ID: NCT05289947 Recruiting - Stroke Clinical Trials

MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits

MAESTOSO
Start date: July 21, 2023
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501 low-dose twice a day, or matching placebo for 24 weeks.

NCT ID: NCT05046106 Not yet recruiting - Stroke Clinical Trials

MLC1501 Study Assessing Efficacy in STROke Recovery

MAEStro
Start date: January 2025
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.

NCT ID: NCT04769310 Recruiting - Stroke Clinical Trials

Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study

Start date: April 26, 2021
Phase: N/A
Study type: Interventional

Demonstrating the pathophysiological link between Left Atrial (LA) and Left Atrial Appendage (LAA) pathology and embolic strokes in non-Atrial Fibrillation (AF) individuals represents a major advance in stroke prevention strategies. Instead of relying on non-specific criteria for stroke risk assessment, the investigators propose to identify individuals with high-risk of embolic stroke using imaging criteria that reflect the underlying pathophysiology of embolic stroke of cardiac origin. the investigators can therefore lay the groundwork for future anticoagulation strategies for stroke prevention beyond AF.

NCT ID: NCT03555474 Completed - Strokes Thrombotic Clinical Trials

Efficacy of the Theta Burst Stimulation and Functional Electrical Stimulation in Stroke Rehabilitation

Start date: October 5, 2009
Phase: N/A
Study type: Interventional

Approximately 50% of patients have persistent motor disability following stroke. Current treatment approaches with conventional physiotherapy have limited efficacy. Repetitive transcranial magnetic stimulation (rTMS) and Functional electrical stimulation (FES) have been shown to improve the neuronal plasticity and motor control in few preliminary studies. Their efficacy in human stroke subjects is unproven. We planned to study their efficacy in improving the motor functions of stroke patients in a randomized trial. Sixty consecutive haemodynamically stable adult patients with first ischemic stroke within last 7-30 days were randomized into three treatment groups to receive either physiotherapy alone, or physiotherapy combined with either FES or rTMS. Outcome was assessed using Fugl Meyer assessment for physical performance of upper limb. Three groups were compared for the outcome measures using intention to treat analysis.

NCT ID: NCT03280641 Completed - Atrial Fibrillation Clinical Trials

D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

DIRECT
Start date: August 9, 2015
Phase: N/A
Study type: Observational

This is a sigle-center, prospective study to evaluate the role of D-Dimer testing in patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.

NCT ID: NCT03098732 Suspended - Stroke, Acute Clinical Trials

Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial

MEDIS
Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation 30-90 minutes after the completion of tPA infusion than subjects treated with IV tPA (plus sham device). Safety of the MED System Procedure will be evaluated by the incidence of symptomatic PH-2 haemorrhagic transformation within 24 hours following the procedure. Lastly, a health economics study will be conducted to estimate health care costs for each treatment.